- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00513279
To Investigate If Single Doses Of GSK618334 Are Safe And To Investigate Blood Levels Of GSK618334
September 14, 2017 updated by: GlaxoSmithKline
A First Time in Human, Blinded, Randomised, Placebo-Controlled, Two-cohort Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single Oral Escalating Doses of GSK618334 in Healthy Male Volunteers
GSK618334 is being developed as an innovative treatment for substance dependence and potentially other compulsive behavioral disorders.
This study will evaluate the safety, tolerability and pharmacokinetics of single doses of GSK618334 in healthy volunteers.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Middlesex
-
Harrow, Middlesex, United Kingdom, HA13UJ
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy adult male subject, aged between 18 and 50 years of age inclusive.
- Body weight ≥50 kg and BMI within the range 18.5-29.9 kg/m2 inclusive.
- Healthy as judged by a responsible physician. No clinically significant abnormality identified on the medical, psychiatric or laboratory evaluation, including 12-lead ECG and 24 hour Holter ECG. A subject with a clinical abnormality or laboratory parameter(s) outside the reference range for this age group may be included only if the Investigator considers the finding will not introduce additional risk factors and will not interfere with the study procedures.
- Signed and dated written informed consent prior to participation in the study.
- The subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.
Exclusion Criteria:
- The subject has a positive pre-study urine drug screen including alcohol at the screening visit and/or prior to receiving the first dose of study medication. Drugs that will be screened for are amphetamines, barbiturates, cocaine, opiates, cannabinoids, methadone, benzodiazepines, phencyclidine (PCP) and cotinine. If any of these tests are positive the investigator may re-test the subject and the subject may be included if the re-test is negative.
- A positive pre-study Hepatitis B surface antigen, Hepatitis C antibody, or HIV 1/2 result at the screening visit.
- Abuse of alcohol defined as an average weekly intake of greater than 28 units or an average daily intake of greater than 4 units.
- The subject has clinically significant elevations in liver function tests (LFT) that are elevated above the reference range at pre-study screening and remain elevated with a repeat LFT, and/or prior to receiving the first dose of study medication.
- Consumption of grapefruit juice or grapefruit within 7 days prior to receiving the first dose of study medication.
- Any subject who is not prepared to eat the standard meals provided by the Clinical Pharmacology Research Unit (CPRU) during the study.
- Participation in a clinical trial with a new chemical entity within 4 months before the first dose of study medication or marketed compound within 3 months before receiving the first dose of study medication.
- Use of prescription or non-prescription drugs, including, over the counter remedies, vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to receiving the first dose of study medication, unless in the opinion of the Investigator and sponsor the medication will not interfere with the study procedures or compromise subject safety.
- Loss of more than 600mL blood during the 120 days before study start.
- History or presence of allergy to the study drug or drugs of this class, or a history of other allergy that, in the opinion of the physician responsible, contraindicates his participation in the study.
- History of regular use of tobacco- or nicotine-containing products within 6 months of the start of the study (i.e., from Screening Visit 1).
- An unwillingness of the male subject to use condoms or practise abstinence to prevent exposure of a female partner to semen from the start of the study (i.e., from Screening Visit 1) until 90 days after the study treatment has ended.
- History of psychiatric disorder either Axis I or II by DSM-IV.
- History or presence of respiratory illnesses, gastrointestinal, hepatic or renal disease or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs.
- The subject has a screening ECG with values outside of ranges defined in the protocol.
- The subject has a screening heart rate <50 or >100 bpm and a systolic blood pressure >140 and <100 mmHg and a diastolic blood pressure >90 and <60 mmHg in the semi-supine position.
- The subject has a reduction in systolic blood pressure of 20 mmHg or more, or a reduction in diastolic blood pressure of 10 mmHg or more on standing compared to the supine measurement at screening.
- History of long QT syndrome (personal or family) or other cardiac conduction disorder, or other clinically significant cardiac disease.
- The subject is unable to abstain from strenuous physical activity for 24 h prior to the screening visit and for 24 h prior to admission for each treatment period.
- Inability of the subject to be successfully trained in tests of cognition prior to receiving the first dose of study medication.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
Subjects in Cohort 1 will be randomized to one of the following sequences: ABDFH, BADFH, BDAFH, BDFAH and BDFHA in a 1:1:1:1:1 ratio where A = Placebo, B= GSK618334 dose 1 (2.5 mg), D = GSK618334 dose 3, F = GSK618334 dose 5, H = GSK618334 dose 7. On day 1, subjects will be administered a starting dose of 2.5 milligrams (mg) GSK618334.
The planned doses of GSK618334 to be administered in Cohort 1 are 2.5, 25, 100 and 400mg.
In each dosing period 2 subjects will receive placebo and 8 subjects will receive GSK618334.
Subjects within a cohort will have a washout period of at least two weeks from last dose before receiving another dose.
|
GSK618334 will be available as white to off-white coated tablets.
GSK618334 will be swallowed with 250 milliliters (mL) of water.
GSK618334 placebo tablets visually match the active GSK618334 tablets and contain the same excipients except for the omission of the active ingredient.
GSK618334 matching placebo will be swallowed with 250 mL of water.
|
Experimental: Cohort 2
Subjects in Cohort 2 will be randomized to one of the following sequences: ACEGI, CAEGI, CEAGI, CEGAI, CEGIA in a 1:1:1:1:1 ratio where A = Placebo, C= GSK618334 dose 2, E = GSK618334dose 4, G = GSK618334 dose 6, I= GSK618334 dose 8.
In each dosing period 2 subjects will receive placebo and 8 subjects will receive GSK618334.
Subjects within a cohort will have a washout period of at least two weeks from last dose before receiving another dose.
|
GSK618334 will be available as white to off-white coated tablets.
GSK618334 will be swallowed with 250 milliliters (mL) of water.
GSK618334 placebo tablets visually match the active GSK618334 tablets and contain the same excipients except for the omission of the active ingredient.
GSK618334 matching placebo will be swallowed with 250 mL of water.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety measures: ECG, Vital Signs, Adverse Events
Time Frame: for 48 hours after dosing.
|
for 48 hours after dosing.
|
PK measures: Blood sampling for GSK598809
Time Frame: for up to 96hr post dose
|
for up to 96hr post dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tests on cognition (thinking)
Time Frame: for 48 hours after dosing
|
for 48 hours after dosing
|
Movement rating scales
Time Frame: pre-dose, 2, 4 and 24 hours post-dose on Day 1
|
pre-dose, 2, 4 and 24 hours post-dose on Day 1
|
Prolactin, TSH and GH
Time Frame: pre-dose, 1, 2, 4, 8 and 24 hours post-dose on Day 1
|
pre-dose, 1, 2, 4, 8 and 24 hours post-dose on Day 1
|
Psychological assessments
Time Frame: pre-dose, up to 48 hours post-dose
|
pre-dose, up to 48 hours post-dose
|
Cognitive/Impulsivity tests
Time Frame: pre-dose, 2, 7 and 24 hours post-dose on Day 1
|
pre-dose, 2, 7 and 24 hours post-dose on Day 1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 28, 2007
Primary Completion (Actual)
October 4, 2007
Study Completion (Actual)
October 4, 2007
Study Registration Dates
First Submitted
August 6, 2007
First Submitted That Met QC Criteria
August 6, 2007
First Posted (Estimate)
August 8, 2007
Study Record Updates
Last Update Posted (Actual)
September 15, 2017
Last Update Submitted That Met QC Criteria
September 14, 2017
Last Verified
September 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DBU107640
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Substance Dependence
-
Medical University InnsbruckCompletedSubstance Abuse | Nicotine Dependence | Tobacco Dependence | Substance DependenceAustria
-
Merck Sharp & Dohme LLCCompletedOpiate Dependence | Substance Dependence | Drug Dependence
-
University of Southern CaliforniaNational Institute on Drug Abuse (NIDA); University of Toronto; RTI InternationalCompletedSubstance Abuse, Intravenous | HIV | Heroin Dependence | Opioid Dependence | Cocaine Dependence | Amphetamine DependenceUnited States
-
University of CincinnatiNational Institute on Drug Abuse (NIDA); MaryhavenUnknownHeroin Dependence | Opiate Dependence | Substance DependenceUnited States
-
California Pacific Medical Center Research InstituteUnknownSubstance Dependence | Amphetamine DependenceUnited States
-
Central Hospital, Nancy, FranceHospital of Jury-les-Metz, France; Healthcare Center of Accompaniment and Prevention...UnknownAlcoholism | Opiate Dependence | Early Satisfaction With Substance Dependence CareFrance
-
University of WashingtonU.S. Army Medical Research and Development CommandCompletedAlcohol Dependence | Substance Abuse | Alcohol Abuse | Substance DependenceUnited States
-
Macmillan Research Group UKNMP Medical Research Institute; Warwick Research ServicesCompletedAlcohol Dependence | Substance Use Disorder | Drug Dependence,India
-
Universidad de AntioquiaCompletedControlled Drug DependenceColombia
-
GlaxoSmithKlineWithdrawnAlcohol Dependence | Substance Dependence
Clinical Trials on GSK618334
-
GlaxoSmithKlineCompletedSubstance DependenceUnited Kingdom